TNBC with higher programmed death ligand-1 (PD-L1) expression, higher tumor mutation burden (TMB), and higher tumor-filtrating lymphocytes (TILs) have been demonstrated to benefit from the treatment of ICI2. Here, CD274 is linked to neoplasm.